Premium
Metabolic atrophy and 3‐ T 1 H ‐magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer
Author(s) -
Panebianco Valeria,
Barchetti Flavio,
Musio Daniela,
Forte Valerio,
Pace Alberto,
De Felice Francesca,
Barchetti Giovanni,
Tombolini Vincenzo,
Catalano Carlo
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12553
Subject(s) - prostate cancer , medicine , radiation therapy , magnetic resonance imaging , magnetic resonance spectroscopic imaging , atrophy , urology , creatine , prostate specific antigen , prostate , cancer , nuclear medicine , gastroenterology , radiology
Objective To correlate 3‐ T magnetic resonance spectroscopic imaging ( MRSI ) with prostate‐specific antigen ( PSA ) levels in patients with prostate cancer treated with external beam radiation therapy to assess the potential advantages of MRSI . Materials and Methods A total of 50 patients (age range 65–83 years) underwent PSA and MRSI surveillance before and at 3, 6, 12, 18 and 24 months after radiotherapy. Results Of the 50 patients examined, 13 patients completely responded to therapy showing metabolic atrophy ( MA ), defined as a choline‐plus‐creatine/citrate ( CC / C ) ratio <0.2, at 3 months; in this group none had biochemical relapse ( PSA nadir + 2 ng/mL) by the end of the follow‐up. Of the 50 patients, 35 showed a partial response to therapy ( CC / C ratio between 0.2 and 0.8) at 3 and 6 months and, of these 35 patients, 30 reached MA at 12 months, while five developed a recurrence ( CC / C ratio >0.8). Three of those patients with recurrence had a biochemical relapse at 18 months and the other two at 24 months. Two of the 50 patients did not respond to the treatment, showing persistent disease from the 3rd month ( CC / C ratio >0.8); one patient had biochemical relapse at 6 and the other at 12 months. Conclusions MRSI was shown to have a greater potential than PSA level in monitoring patients after radiotherapy, because it anticipates PSA nadir, and biochemical relapse in particular.